“Treatment of pediatric patients with relapsed and refractory high-grade glioma and ependymoma is extremely challenging. There are limited treatment options and high unmet clinical need for patients suffering from this aggressive cancer,” said Dr.
The open-label study (NCT05610891) will assess two dosing regimens to identify the optimal iopofosine I 131 Phase 2 recommended dose and schedule in pHGG patients and evaluate safety and tolerability. The study is supported by a
“We understand the profound impact pediatric high-grade gliomas have on the lives of young patients and their families,” commented
About Pediatric High-Grade Gliomas (pHGG)
Pediatric high-grade gliomas are aggressive malignant tumors that form in the brain or spinal cord of children, adolescents, and young adults. Comprising a small but devastating portion of childhood cancers with an approximate incidence rate of 1,300 patients in the US (1.1-1.178 per 100,000 children), these tumors originate in the glial cells of the brain and spinal cord and are known for their rapid growth and resistance to conventional treatments. They are also responsible for over 40% of childhood brain tumor death and are the more common cause of tumor related death for children. The current standard of care for pediatric high-grade gliomas typically involves a combination of extensive brain surgery, radiation therapy, and chemotherapy at the time of initial diagnosis. However, the outcomes remain unsatisfactory for newly diagnosed patients and are dismal for relapsed or progressive disease. The five-year overall survival rate for high-grade gliomas in children is less than 20% and limited improvements were seen over the years. The disease's aggressive clinical nature and inherent genomic resistance often leads to significant challenges in achieving long-term remission and therapies with new mechanisms of action are urgently needed.
About
The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Forward-Looking Statement Disclaimer
This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes including our expectations regarding the WM CLOVER-WaM pivotal trial. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to maintain orphan drug designation in
Contacts
MEDIA:
315-765-1462
clacagnina@blissbiohealth.com
INVESTORS:
Chief Financial Officer
investors@cellectar.com
Source:
2024 GlobeNewswire, Inc., source